TP53 and acute myeloid leukemia: Lindsley et al. reported that the proportion of patients with secondary-type or TP53-mutated t-AML requiring two or more rounds of induction IC to achieve a CR was higher than the corresponding proportion of patients in the pan/de novo AML group.